AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04522973 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Beverage with ethanol and E-cigarette liquid without ethanol
Description: Beverage with ethanol and E-cigarette liquid without ethanol
Study NCT04522973 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Beverage without ethanol and E-cigarette liquid with ethanol
Description: Beverage without ethanol and E-cigarette liquid with ethanol
Study NCT04522973 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Beverage without ethanol and E-cigarette liquid without ethanol
Description: Beverage without ethanol and E-cigarette liquid without ethanol
Study NCT04926103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota transplant (FMT)
Description: Patients will come once a week for FMT for 8 weeks. FMT is the administration of the supernatant component of stool and water mixture from a healthy relative or an unrelated donor. The donor's stool and blood is rigorously screened to exclude known communicable diseases. Those that achieve remission with FMT will have the option of continuing FMT once per month for 3 years
Study NCT06090903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: patients will receive 1-3 image-guided biopsies within tumor tissue already designated for resection or removal.
Study NCT06090903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI scan
Study NCT06090903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Review Medical Chart
Study NCT05969392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intradiscal Gelified Ethanol
Description: Intradiscal percutaneous injection of an intradiscal Gelified Ethanol
Study NCT04550676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT (intervention)
Description: Following a 5-minute warm-up, high and moderate-intensity exercise bouts will alternate: a five bouts of 4-minute high-intensity exercise (90% VO2peak) will alternate with four 3-minute bouts of moderate-intensity exercise (50% VO2peak) by week 8. This is followed by a 5-minute cool-down. The total exercise time will be 42 minutes. For resistance exercise, the initial goal will be to complete 3 sets of 8-10 repetitions of 3 exercises at low intensity (50% 1-RM) and then progress to moderate intensity (70-80% 1-RM). Exercise intensity will increase every 4 weeks or when participants can complete more than 8 repetitions with proper form at the prescribed weight.
Study NCT04550676 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CME (active control)
Description: Following a 4-minute warm-up, the participant will walk/jog for up to 42 continuous minutes at 60% VO2peak. This is followed by a 4-minute cool-down. The total exercise time is 50 minutes. For resistance exercise, the initial goal will be to complete 3 sets of 8-10 repetitions of 3 exercises at low intensity (50% 1-RM) and then progress to moderate intensity (70-80% 1-RM). Exercise intensity will increase every 4 weeks or when participants can complete more than 8 repetitions with proper form at the prescribed weight.
Study NCT05272735 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccine (Recombinant)
Description: Hepatitis B Vaccine (Recombinant) 20 mcg intramuscular injection at 0-1-6 months
Study NCT03417921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABTL0812
Description: ABTL0812 in combination with gemcitabine and nab-paclitaxel
Study NCT03417921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and nab-paclitaxel
Description: Gemcitabine and nab-paclitaxel as standard pattern
Study NCT03417921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine and nab-paclitaxel
Description: Gemcitabine and nab-paclitaxel as standard pattern
Study NCT04992936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extract from the wine industry
Description: The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
Study NCT04992936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
Study NCT05970549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRRAflow® Active Fluid Exchange System
Description: All patients in the prospective arm of the study who met the study criteria and consent will be enrolled in the IRRAflow with Active Fluid Exchange arm.~Insertion of the IRRaflow catheter will be performed by neurosurgical attendings and residents who are privileged to place external ventricular drains and who have be instructed on how to appropriately connect the inserted IRRAflow catheter to the system. The on-site IRRAflow instructor will be present and available at all time to assist with any issues or questions should they arise.
Study NCT05970549 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional extraventricular drain
Description: The retrospective analysis will be performed on the last 60 traditional external ventricular drains.
Study NCT05970549 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-contrast head CTs
Description: Non-contrast head CTs will be performed at least every 48 hours to document effectiveness. This frequency is standard, if not more frequent as necessary, for patients with external ventricular drainage and intraventricular hemorrhage. Scans are routinely obtained at this frequency to evaluate, for example: evacuation of hemorrhage, admission pathology, post-placement of catheters, any change in neurological exam, or after elevations in intracranial pressure. With these common CT scans we will be able to assess the efficacy of the IRRAflow catheter on the specified parameters. These scans are routinely performed due to this pathology and as such are covered as a necessity of the hospitalization by the insurance companies. MRI may be used in place of a CT scan if medically indicated as determined by the neurosurgical attending or neurocritical care attending according to standard of care for treatment of the neurological pathology.
Study NCT06504953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaires on contraception and sports activities
Study NCT06504953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beighton test
Description: A popular screening technique for hypermobility. It consists of a nine-point scale requiring the performance of five maneuvers, four passive bilateral and one active unilateral.
Study NCT06504953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lachman Test
Description: To perform this test, place your patient in a supine position and bring your patient's test leg to 30 degrees of flexion. Fix the femur with the other hand. Put the tibia in slight external rotation, then try to translate it forwards.~This test is positive if you feel a soft or limp end or if the anterior part.
Study NCT06506643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc-64 Aspartate
Description: KLS-1 drug substance is Zinc Aspartate enriched with isotope Zinc-64 to 99.2% mass fraction of total Zinc. KLS-1 investigational medicinal product (IMP) is formulated as a solution, containing 25.64 mg of drug substance in 1 ml and inactive ingredients (water for injections, USP, EuPh).
Study NCT06271668 — intervention group
Intervention type: OTHER
Intervention: Naloxone Co-prescribing Clinical Decision Support (CDS)
Description: Clinical decision support in the form of an EHR-integrated, provider facing alert suggesting (a) the opioid medication order is considered high risk for overdose and (b) to nudge providers to add a naloxone prescription to the opioid prescription to mitigate risk in the event of an overdose.
Study NCT05525572 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave Therapy (SWT)
Description: Shockwave Therapy (SWT):~720 shocks will be administered administered in every session to each treated region (left and right corpora cavernosa and crura). Each session will last approximately 20 minutes. A total of 3600 shocks will be administered over 5 weekly sessions.
Study NCT05525572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Platelet-Rich Plasma (PRP)
Description: Autologous Platelet Rich Plasma (PRP):~5 mL PRP will be administered via intra-cavernous penile injection with a 30 ± 7 day treatment interval.
Study NCT06191328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiglitazar sodium
Description: In patients with type 2 diabetes mellitus (T2DM), on the basis of one or two oral hypoglycemic agents combination with Chiglitazar sodium.
Study NCT06648564 — intervention group
Intervention type: PROCEDURE
Intervention: Bone regenerative surgery with a bone graft substitute and a resorbable membrane
Description: Dental implants with a diagnosis peri-implantitis were treated with regenerative surgery.
Study NCT04782453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ToQuit, a technology delivered tobacco cessation intervention
Description: The intervention messages will consist of specific content areas derived from the formative research of the study. Some of the components of the intervention include~* Psychoeducation about consequences of tobacco use and benefits of quitting;~* goal setting;~* managing goals and self-monitoring of behavior;~* avoidance strategies;~* self-awareness and reflection messages;~* social and pharmacological support, and help-seeking;~* identifying and managing cravings;~* relapse prevention strategies.
Study NCT04782453 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tobacco quitting helplines
Description: Participants from the control group will be sent the details of other functional tobacco helplines in India.
Study NCT05468242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant chemo-immunotherapy
Description: The neoadjuvant chemo-immunotherapy before radiotherapy comprised of chemotherapy plus Tislelizumab \[200 mg, once every 3 weeks (Q3W)\].
Study NCT05468242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemo-immunotherapy
Description: The neoadjuvant chemo-immunotherapy before radiotherapy comprised of chemotherapy plus Tislelizumab \[200 mg, once every 3 weeks (Q3W)\].
Study NCT05468242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: The Bevacizumab was administrated concurrently with neoadjuvant chemo-immunotherapy (7.5mg/kg) once every 3 weeks (Q3W).
Study NCT05468242 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Definitive radiotherapy to the thoracic lesions.
Study NCT05468242 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Definitive radiotherapy to the thoracic lesions.
Study NCT05468242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: Tislelizumab consolidation (200 mg) is performed once every 3 weeks after the neoadjuvant therapy and concurrent chemo-radiotherapy, and will continue on a Q3W schedule for a maximum duration of 12 months.
Study NCT05468242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab consolidation (200 mg) is performed once every 3 weeks after the neoadjuvant therapy and concurrent chemo-radiotherapy, and will continue on a Q3W schedule for a maximum duration of 12 months.
Study NCT05742360 — intervention group
Intervention type: DEVICE
Intervention: CPAP therapy
Description: CPAP treatment of obstructive sleep apnea with the excessively sleepy symptom subtype
Study NCT05098912 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual acupuncture
Description: Manual acupuncture using filiform needle
Study NCT05098912 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thread embedding acupuncture
Description: Thread Embedding acupuncture using Polydioxanone thread
Study NCT05523193 — intervention group
Intervention type: OTHER
Intervention: Formal treatment model
Description: Formal treatment model , no further surgery or minimally invasive treatment was performed
Study NCT06339164 — intervention group
Intervention type: OTHER
Intervention: skills and learning quality in breech delivery
Description: evaluation of different skill retention and learning quality after different learning methods
Study NCT05303064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLZ/SAM
Description: OLZ/SAM refers to the fixed dose combination of olanzapine and samidorphan. The starting dose of olanzapine will be 2.5 mg/day or 5 mg/day at the discretion of the Investigator with a maximum daily dose of 20mg/day. The starting dose of samidorphan will be 5 or 10 mg.
Study NCT05303064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: The starting dose of olanzapine will be 2.5 mg/day or 5 mg/day at the discretion of the Investigator with a maximum daily dose of 20mg/day
Study NCT04550975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advanced Cognitive Stimulation Therapy
Description: An adapted version of Cognitive Stimulation Therapy for people with moderate to severe dementia.
Study NCT05040672 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionare online application
Description: questionare online application
Study NCT04805580 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: unilateral intrathecal block
Description: Quadratus lunborum block
Study NCT06440356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laser therapy
Description: low level laser therapy applied
Study NCT05556161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Practitioners and Diabetes Specialists Co-management
Description: Self-monitoring of blood glucose: Participants will monitor blood glucose with a a free intelligent home blood glucose meter. Then, the intelligent blood glucose meter will upload data to the platform.~Glycosylated hemoglobin check: Participants will receive HbA1c test once every three months.~Cooperative General Practitioner-Specialist Management: Based on the remote monitoring of blood glucose and HbA1c tests, general practitioners and specialists will jointly carry out management measures including health education, medication adjustment, outpatient consultation, referral, case discussion, etc. for participants.
Study NCT05538234 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory values - baseline
Description: Baseline laboratory values will be obtained
Study NCT05538234 — intervention group
Intervention type: OTHER
Intervention: Medical information 12 hours before organ harvesting
Description: * average hourly diuresis~* hypotension MAP\<65 Torr longer than 30 minutes (YES/NO)~* Furosemide administration (YES/NO)~* Mannitol administration (YES/NO)~* administration of anti-diuretic hormone (YES/NO)~* administration of vasopressors (YES/NO)~* polyuria >3ml/kg/h (YES/NO)~* nephrotoxic agents during hospitalization (YES/NO)
Study NCT05538234 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory values - 12 hours after reperfusion
Description: Laboratory values will be obtained 12 hours after reperfusion
Study NCT05538234 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory values - 48 hours after reperfusion
Description: Laboratory values will be obtained 48 hours after reperfusion
Study NCT05538234 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory values - 7 days after reperfusion
Description: Laboratory values will be obtained 7 days after reperfusion
Study NCT05538234 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory values - 90 days after reperfusion
Description: Laboratory values will be obtained 90 days after reperfusion
Study NCT05538234 — intervention group
Intervention type: OTHER
Intervention: Medical information during organ harvesting/transplantation
Description: Medical information during organ harvesting/transplantation~* hypotension MAP 65 Torr > 5 minutes (YES/NO)~* vasopressor support (YES/NO, duration in minutes)
Study NCT05538234 — intervention group
Intervention type: PROCEDURE
Intervention: Organ harvesting
Description: Organ harvesting for transplant
Study NCT05538234 — intervention group
Intervention type: PROCEDURE
Intervention: Organ transplantation
Description: Transplantation of the harvested organ
Study NCT06174298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor (Filgrastim)
Description: Intervention Group Fresh Embryo Transfers: On day 5 or 6 of culture, viable embryos will be transferred into a center-well dish containing 1 mL of embryo transfer media supplemented with GCSF. The embryos will be cultured in this medium for approximately 3 hours before the embryo transfer (ET) procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.~Intervention Group Frozen Embryo Transfers: Cryopreserved embryos will be thawed according to the Kitazato thawing protocol and will be subsequently transferred to a center-well dish containing 1 mL of embryo transfer media supplemented with GCSF. The embryos will be cultured in this medium for approximately 3 hours before the ET procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.
Study NCT06174298 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Embryo Transfer Media
Description: Control Group Fresh Embryo Transfers: On day 5 or 6 of culture, viable embryos will be transferred into a center-well dish containing 1 mL of embryo transfer media. The embryos will be cultured in this medium for approximately 3 hours before the embryo transfer (ET) procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.~Control Group Frozen Embryo Transfers: Cryopreserved embryos will be thawed according to the Kitazato thawing protocol and will be subsequently transferred to a center-well dish containing 1 mL of embryo transfer media. The embryos will be cultured in this medium for approximately 3 hours before the ET procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.
Study NCT06028074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIM122
Description: GIM-122 administered IV once every 3 weeks
Study NCT06493123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Cardiopulmonary Rehabilitation
Description: Conventional cardiopulmonary applications including positioning, chest physiotherapy, in-bed normal joint movement exercises, sitting and walking, posture exercises
Study NCT06493123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bottle P.E.P. (Pozitive Expiratory Pressure)
Description: The device will be built according to the optimal design parameters for a positive expiratory pressure therapy bottle device established by Mestriner et al. According to this~Bottle-P.E.P. device:~* PEP: 10-20 cmH2O~* Inspiration: Expiration Ratio: 1:3-4~* Material Used: Open top plastic bottle, plastic pipe.~Plastic Bottle Specifications:~I. Material-Hard Plastic II. Dimensions-Weight- 40grams; Height- 25cm; Width- 10cm; Perimeter- 20cm III. Water column height- 13cm~Plastic Pipe Properties:~I. Material-Pipette II. Inner Diameter- ≥8mm III. Pipe Length- 30cm IV. Depth in the water column - 10cm; 3 cm above the bottom of the bottle surface.~- The distal end of the tube used in the Bottle P.E.P. will be placed 10 cm below the surface, i.e. 10 cm water column and 3 cm above the bottom of the bottle, and the device will be placed on a table in front of the participant.
Study NCT06493123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Mobilization
Description: The Maebashi mobilization protocol will be followed for early mobilization program. According to this protocol, the hemodynamic and respiratory parameters of the patient will be evaluated first and the patient who meets the criteria for the mobilization program will be started to the mobilization program according to the appropriate stage of the 5-stage mobilization protocol.~In Maebashi Mobilization protocol:~Level 1: No mobilization and in-bed passive exercise Level 2: Supported in-bed sitting and in-bed active/assistive-active exercise Level 3: Unassisted sitting on the edge of the bed Level 4: Active transfer to chair Level 5: Standing, stepping in place and supported walking about 10 meters (with support of 2 people)
Study NCT06078358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: Traditional linear periodization resistance training.
Study NCT05605717 — intervention group
Intervention type: RADIATION
Intervention: Fibroscan
Description: Liver fibroscan and ultrasonography
Study NCT06268444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7-day actimetry sleep recording
Description: 7-day actimetry sleep recording
Study NCT06268444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Determination of environmental pollutants in breast milk
Description: Determination of environmental pollutants in breast milk
Study NCT06268444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurements of environmental pollutants in indoor air deposited on the bracelet worn by the child
Description: Measurements of environmental pollutants in indoor air deposited on the bracelet worn by the child
Study NCT06268444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous recording of the child&#39;s temperature for 7 days
Description: Continuous recording of the child\&#39;s temperature for 7 days
Study NCT06268444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of a sleep diary for 7 days
Description: Use of a sleep diary for 7 days
Study NCT06268444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parental questionnaire of environmental exposure
Description: Parental questionnaire of environmental exposure